You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Inhibitors of T3SS translocon assembly to combat multi-drug resistant P. aeruginosa

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    Abstract Pseudomonas aeruginosa (PA) is the bacterium most frequently isolated from the respiratory tract of ICU pa- tients in the US and is a major cause of pneumonia in intubated patients. Furthermore, infection with PA gener- ally has a poor prognosis, with an estimated 40-69% of PA ventilator-associated pneumonia (VAP) cases re- sulting in mortality, and more than 30% of survivors suffer recur ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Development of EFTX-001 to target KRAS mutations in cancer

    SBC: Enfuego Therapeutics Inc.            Topic: 102

    Research Summary: The KRAS proto-oncogene is one of the most critical genes in cancer, yet it has also proven to be among the most elusive. Nearly all (98%) of KRAS missense mutations occur in codons 12 or 13, which leads to constitutive KRAS activation and promotion of numerous cancer hallmarks. Although kinase inhibitors have revolutionized treatment of some subsets of cancers driven by other mo ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Inhaled Fasudil and DETA NONOate CAR-Targeted Liposomes for PAH

    SBC: VASCULAR BIOSCIENCES, INC.            Topic: NHLBI

    Pulmonary arterial hypertension (PAH) affects ~15-50 individuals per million and claims ≥20,000 lives annually in the United States. It affects every ethnic group, race, age and gender, and devastates high-risk patients afflicted with HIV, systemic sclerosis, and sickle cell disease. The disease affects more women than men; adult PAH patients do not live more than five years after the diagnosis. ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Personalized anesthetic brain monitoring:Developing novel systems, sensors, and algorithms for aging, dementia, and Alzheimers disease patients

    SBC: PASCALL Systems, Incorporated            Topic: R

    PROJECT SUMMARY In the United States, nearly 100,000 patients receive general anesthesia and sedation daily to safely undergo surgical and non-surgical procedures. A high proportion of these patients are older than 65 years of age. These older patients are at higher risk of post-operative delirium and cognitive dysfunction. Many of these older patients have dementia, including mild cognitive impai ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Enhanced MDx: a computational model to optimize pre-analytical pathogen isolation from whole blood.

    SBC: Redbud Labs, Inc.            Topic: 400

    ABSTRACT Microscale simulations have been applied to a number of complex microfluidic systems and biological applications, but existing methods are limited in the scale and scope of problems that are addressable. Thermodynamically constrained averaging theory (TCAT) is an established approach that can be used to formulate customized macroscale models that are consistent with microscale physics and ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. A new generation, enhanced, corneal-birefringence-independent retinalscanning device for pediatric vision disorders using polarization modulation

    SBC: REBISCAN, Inc.            Topic: N

    Project Summary/Abstract !Amblyopia is vision loss caused by neglect of a structurally normal eye due to strabismus, asymmetric refraction (anisometropia), or deprivation. It is irreversible if not treated by age 7, but half of all patients in the U.S. are undetected and untreated until after it is too late, making it the leading cause of preventable vision loss. Rebion (Rebiscan, Inc) has develop ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Development of gene therapy product for treating MPS IIIB

    SBC: NEUROGT, INC.            Topic: NINDS

    Project Summary NeuroGT, Inc is a new start-up company founded by Dr. Haiyan Fu, Associate professor in the Gene Therapy Center at University of North Carolina at Chapel Hill, with the mission of develop and commercialize effective gene therapy products to treat rare neurogenetic diseases in humans. The goal of this project is to develop an effective gene therapy product targeting the root cause f ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Prevention of corneal transplant rejection using AAV-HLA-G combination therapy

    SBC: Bedrock Therapeutics, Inc.            Topic: NEI

    Abstract Corneal blindness is a leading cause of global blindness, with allogeneic corneal transplantation (CT) being the most common form of tissue transplantation worldwide. Though approximately 180,000 CT surgeries are carried out each year, around 12.7 million are currently awaiting a donor cornea to undergo the operation. Still, CT surgery is accompanied by a high failure rate: as many as 20 ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating sepsis

    SBC: Arrevus, Inc.            Topic: NIAID

    PROJECT SUMMARYSepsis is a life-threatening syndrome that involves a systemic inflammatory response that is initiated by an infection. There are an estimated 1.5 million of cases annually in the US with 250,000 resulting in death. The number of cases and associated deaths is expected to increase given the rising at-risk population of elderly individuals and the compounding challenge of antibiotic ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Examination of a novel potential therapy for autonomic dysreflexia

    SBC: Dignify Therapeutics LLC            Topic: NINDS

    PROJECT SUMMARY/ABSTRACT Autonomic dysreflexia (AD) is a potentially life-threatening hypertensive crisis that predominantly affects individuals with a spinal cord injury (SCI) above T6. AD can be triggered idiopathically or by distention or manipulation of pelvic visceral organs, especially the bladder and bowel, which can occur with catheterization and fecal evacuation procedures that are necess ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government